Retinal degeneration of high myopia
Conditions
Interventions
HM macular disease stage A2, treatment group:Oral Yijing Tongluo prescription granules
HM macular disease stage A2, control group:Oral placebo granules
HM macular disease stage A1, control group:Oral placebo granules
HM macular disease stage A1, treatment group:Oral Yijingyangxue prescription granules
Sponsors
Eye Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Diopter = -6.00D and axial length = 26mm 2. Age :20-60 3.HM patient had stage A1 macular lesions and qi and blood deficiency syndrome: if the patient met 1 main symptom +1 secondary symptom, he could be included in the group 4.HM patient had stage A2 macular lesions and qi deficiency and blood stasis syndrome: if the patient met 1 main symptom +1 secondary symptom, he could be included in the group 5. Other vasodilators or neurotrophic drugs are being used and can be included after 1 month of drug withdrawal 6. Informed consent has been signed
Exclusion criteria
Exclusion criteria: 1. Have HM macular cleft, retinal hiatus, neovascularization, retinal detachment, glaucoma and other fundus lesions 2. Accompanied by cardiac, hepatic and renal insufficiency 3. Patients who are participating in clinical trials of other drugs or who are using the same traditional Chinese medicine and other treatments together 4. Patients suffering from hypertension, diabetes and other systemic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total retinal blood flow density in macular area; | — |
Secondary
| Measure | Time frame |
|---|---|
| Spherical Equivalent Refraction;Mean retinal thickness in macular area;The thickness of the mGCC;TCM syndrome score;best corrected visual acuity;axial length;Choroid thickness under macular fovea; | — |
Countries
China
Contacts
Public ContactLianrong Yin
Outcome results
None listed